(Q43470197)

English

Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan

scientific article published on 10 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

10

object named as

Namiki Izumi

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

Haruhiko Takeda

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Hiroki Nishikawa

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Yukio Osaki

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Kaoru Tsuchiya

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Kouji Joko

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Chikara Ogawa

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Hiroyoshi Taniguchi

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Etsuro Orito

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Yasushi Uchida

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Japanese Red Cross Liver Study Group

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

publication date

10 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1581-1589

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Treatment for hepatocellular carcinoma in elderly patients: a literature review

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Targeted therapies for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Appropriate BMI for Asian populations

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12591

21 January 2018

Identifiers

10.1111/LIV.12591

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43470197&oldid=1989591355"